The Journal of Immunology · 2010 · 78 citations · 27 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyDendritic Cell BiologyImmune Cell InfiltrationT Cell ActivationT Cell Responses To TumorsCd4 Positive T Cell ResponsesCd4 T Cell ActivationCd4+ Tumor-infiltrating LymphocytesCd40l SignalingCd8 Positive T Cell ResponsesCd8+ Tumor-infiltrating LymphocytesImmunotherapy For Ovarian CancerT-cell Immune Responses
T cell adoptive transfer strategies that have produced clinical remissions against specific tumors have so far produced disappointing results against ovarian cancer. Recent evidence suggests that adoptively transferred CD4(+) T cells can trigger endogenous immune responses in particular patients with ovarian cancer through unknown mechanisms. However, conflicting reports suggest that ovarian cancer-infiltrating CD4(+) T cells are associated with negative outcomes. In this study, we elucidate the phenotypic attributes that enable polyclonal CD4(+) T cells briefly primed against tumor Ags to induce therapeutically relevant endogenous antitumor immune responses. Our results unveil a therapeutic mechanism whereby tumor-primed CD4(+) T cells transferred into ovarian cancer-bearing mice secrete high levels of CCL5, which recruits endogenous CCR5(+) dendritic cells to tumor locations and activate them through CD40-CD40L interactions. These newly matured dendritic cells are then able to prime tumor-specific endogenous CD8(+) T cells, which mediate long-term protection. Correspondingly, administration of tumor-primed CD4(+) T cells significantly delayed progression of MHC class II(-) ovarian cancers, similarly to CD8(+) T cells only, and directly activated wild-type but not CD40-deficient dendritic cells recruited to the tumor microenvironment. Our results unveil a CCL5- and CD40L-dependent mechanism of transferring immunity from exogenously activated CD4(+) T cells to tumor-exposed host cells, resulting in sustained antitumor effects. Our data provide a mechanistic rationale for incorporating tumor-reactive CD4(+) T cells in adoptive cell transfer immunotherapies against ovarian cancer and underscore the importance of optimizing immunotherapeutic strategies for the specific microenvironment of individual tumors.
27
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Lin Zhang, José R. Conejo-García, Dionyssios Katsaros et al. · New England Journal of Medicine · 2003 · 3.4K citations · Full text
Medicine, Immunology, Oncology +17
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins et al. · Science · 2002 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17
Eiichi Sato, Sara H. Olson, Jiyoung Ahn et al. · Proceedings of the National Academy of Sciences · 2005 · 2.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Sally R.M. Bennett, Freda Karamalis, Richard A. Flavell et al. · Nature · 1998 · 2.1K citations
Marina Cella, Doris Scheidegger, Kathrin Palmer-Lehmann et al. · The Journal of Experimental Medicine · 1996 · 2K citations · Full text